


Accepted Manuscript

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia

Merel L. Hartgers, MD, Joep C. Defesche, PhD, Gisle Langslet, MD, Paul N. Hopkins, MD, MSPH, John J.P. Kastelein, MD, PhD, FESC, Marie T. Baccara-Dinet, MD, MSc, Werner Seiz, MD, Sara Hamon, MA, PhD, Poulabi Banerjee, PhD, Claudia Stefanutti, MD, PhD



PII: S1933-2874(17)30543-3

DOI: [10.1016/j.jacl.2017.12.008](https://doi.org/10.1016/j.jacl.2017.12.008)

Reference: JACL 1230

To appear in: *Journal of Clinical Lipidology*

Received Date: 17 November 2017

Revised Date: 14 December 2017

Accepted Date: 15 December 2017

Please cite this article as: Hartgers ML, Defesche JC, Langslet G, Hopkins PN, Kastelein JJP, Baccara-Dinet MT, Seiz W, Hamon S, Banerjee P, Stefanutti C, Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia, *Journal of Clinical Lipidology* (2018), doi: 10.1016/j.jacl.2017.12.008.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia

Merel L. Hartgers MD^a, Joep C. Defesche PhD^b, Gisle Langslet MD^c, Paul N. Hopkins MD, MSPH^d, John J. P. Kastelein MD, PhD, FESC^a, Marie T. Baccara-Dinet MD, MSc^e, Werner Seiz MD^f, Sara Hamon MA, PhD^g, Poulabi Banerjee PhD^g, Claudia Stefanutti MD, PhD^{h,*}

^aDepartment of Vascular Medicine, Academic Medical Center, Amsterdam, the

Netherlands; ^bDepartment of Clinical Genetics, Academic Medical Centre,

Amsterdam, the Netherlands; ^cLipid Clinic, Oslo University Hospital, Oslo, Norway;

^dSchool of Medicine, University of Utah, Salt Lake City, Utah, USA; ^eCardiovascular

R&D, Sanofi, Montpellier, France; ^fTranslational Medicine and Early Development,

Sanofi, Frankfurt, Germany; ^gTranslational Medicine, Regeneron Pharmaceuticals,

Inc., New York, New York, USA; ^hDepartment of Molecular Medicine, 'Sapienza'

University of Rome, Umberto I Hospital, Rome, Italy

Running title: Alirocumab efficacy in pts with >1 FH mutations

*Corresponding author. Extracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Immunohematology and Transfusion Medicine, Department of Molecular Medicine, 'Sapienza' University of Rome, Umberto I Hospital, Rome, Italy.

E-mail address: claudia.stefanutti@uniroma1.it

Download English Version:

<https://daneshyari.com/en/article/8668410>

Download Persian Version:

<https://daneshyari.com/article/8668410>

[Daneshyari.com](https://daneshyari.com)